IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

@article{Clappier2015IKZF1DI,
  title={IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951},
  author={Emmanuelle Clappier and Nathalie Grardel and M Bakkus and J{\'e}r{\^o}me Rapion and Barbara de Moerloose and Peter Kastner and Aur{\'e}lie Caye and Jocelyne Vivent and Vittorio Costa and Alice Ferster and Patrick Lutz and Françoise Mazingue and Fr{\'e}d{\'e}ric Millot and Dominique Plantaz and Genevi{\`e}ve Plat and Emannuel Plouvier and Marilyne Poir{\'e}e and Nicolas Sirvent and Anna Uyttebroeck and Karima Yakouben and Sandrine Girard and Nicole Dastugue and Simona Suciu and Yves Benoit and Yves Bertrand and H{\'e}l{\`e}ne Cav{\'e}},
  journal={Leukemia},
  year={2015},
  volume={29},
  pages={2154-2161}
}
The added value of IKZF1 gene deletion (IKZF1del) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We performed a comprehensive analysis of the impact of IKZF1del in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG trial 58951. Patients with IKZF1del had a… CONTINUE READING

3 Figures & Tables